Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Matthew Rabinowitz, Executive Chairman of Natera, Inc. (NASDAQ:NTRA), recently sold 54,000 shares of common stock, resulting in proceeds of approximately $8.38 million. The sales occurred between May 15 and June 13, with prices ranging from $150.2 to $165.85 per share. The stock, currently trading at $171.86, has delivered a remarkable 60.45% return over the past year and is approaching its 52-week high of $183.
Specifically, the sales were executed in multiple transactions. On May 15, 10,000 shares were sold at $150.20 per share. On May 16, two transactions occurred: 10,000 shares at $152.60 and 9,000 shares at $153.10. On May 20, 10,000 shares were sold at $153.90. A further 10,000 shares were sold on May 28 at $161.00, and finally, on June 13, 5,000 shares were sold at $165.85. According to InvestingPro analysis, the stock appears overvalued at current levels, with analysts setting price targets ranging from $37 to $251.
Following these transactions, Rabinowitz continues to indirectly own 30,000 shares through his spouse, and directly owns 2,362,570 shares of Natera, Inc. With a market capitalization of $23.49 billion, Natera shows strong momentum despite its volatile price movements. InvestingPro subscribers can access 13 additional key insights and a comprehensive Pro Research Report about Natera’s financial health and future prospects.
In other recent news, Natera reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of -$0.50, compared to a forecast of -$0.64. The company achieved revenue of $522 million, reflecting a 37% increase from the previous year. Following the earnings announcement, Natera raised its full-year revenue guidance to between $1.94 billion and $2.02 billion. RBC Capital Markets maintained an Outperform rating on Natera and kept a price target of $251, citing the company’s strong quarterly performance and increased guidance. TD Cowen analysts also showed a positive outlook, raising their price target from $195 to $200, highlighting Natera’s 13% higher-than-expected sales and a significant increase in Signatera’s clinical volumes. Additionally, Natera announced that Medicare has expanded coverage for its Signatera MRD assay, now including a broader range of cancers such as colorectal, breast, bladder, ovarian, and lung cancers. Leerink Partners reiterated an Outperform rating for Natera, maintaining a price target of $220, following Medicare’s decision to cover the WGS Signatera assay. These developments reflect Natera’s ongoing expansion and strong market position, as noted by analysts and recent Medicare coverage updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.